Company · CIK 0001606645 · SIC 2833 — Medicinal Chemicals & Botanical Products
Foamix Pharmaceuticals Ltd. · FOMX
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 5, 2019 PForm 4 → | Mar 6, 4:07 pm EST | Matthew T. WileyChief Commercial Officer | 13,440 | $3.76 | $50,534 | 63,440 | +26.9% | plan? |
| Jan 1, 2019 AForm 4 → | Jan 3, 4:09 pm EST | Ilan HadarCFO & Country Manager | 40,712 | — | — | 133,091 | — | plan? |
| Jan 1, 2019 AForm 4 → | Jan 3, 4:08 pm EST | Iain StuartChief Scientific Officer | 32,569 | — | — | 66,171 | — | plan? |
| Jan 1, 2019 AForm 4 → | Jan 3, 4:06 pm EST | Mutya HarschCLO and General Counsel | 30,127 | — | — | 55,127 | — | plan? |
| Jan 1, 2019 AForm 4 → | Jan 3, 4:04 pm EST | David DomzalskiCEO, Director | 73,282 | — | — | 219,691 | — | plan? |
| Dec 3, 2018 SForm 4 → | Dec 6, 6:06 am EST | David DomzalskiCEO, Director | 68 | $4.05 | $275 | 146,409 | −0.05% | plan? |
| Dec 3, 2018 AForm 4 → | Dec 4, 4:05 pm EST | Matthew T. WileyChief Commercial Officer | 50,000 | — | — | 50,000 | — | plan? |
| Nov 26, 2018 PForm 4 → | Dec 6, 6:09 am EST | Aharon SchwartzDirector | 112,200 | $3.90 | $437,773 | 112,200 | — | plan? late |
| Nov 19, 2018 SForm 4 → | Nov 20, 4:07 pm EST | David DomzalskiCEO, Director | 5,036 | $3.90 | $19,640 | 146,477 | −3.32% | plan? |
| Nov 19, 2018 SForm 4 → | Nov 20, 4:05 pm EST | Alvin D HowardVP Regulatory | 3,375 | $3.90 | $13,163 | 38,414 | −8.08% | plan? |
| Nov 8, 2018 SForm 4 → | Nov 13, 6:16 am EST | Iain StuartSVP R&D | 683 | $4.58 | $3,128 | 33,602 | −1.99% | plan? late |
| Nov 8, 2018 SForm 4 → | Nov 13, 6:13 am EST | David DomzalskiCEO, Director | 2,062 | $4.58 | $9,444 | 151,513 | −1.34% | plan? late |
| Oct 1, 2018 SForm 4 → | Oct 2, 5:22 pm EDT | Alvin D HowardVP Regulatory | 234 | $5.81 | $1,360 | 41,789 | −0.56% | plan? |
| Oct 1, 2018 SForm 4 → | Oct 2, 5:20 pm EDT | Russell P. ElliottVP Drug Development | 142 | $5.81 | $825 | 12,442 | −1.13% | plan? |
| Oct 1, 2018 SForm 4 → | Oct 2, 5:18 pm EDT | David DomzalskiCEO, Director | 601 | $5.81 | $3,492 | 153,575 | −0.39% | plan? |
| Sep 4, 2018 SForm 4 → | Sep 6, 4:05 pm EDT | David DomzalskiCEO, Director | 67 | $5.67 | $380 | 154,176 | −0.04% | plan? |
| Aug 8, 2018 SForm 4 → | Aug 9, 4:07 pm EDT | David DomzalskiCEO, Director | 8,238 | $5.68 | $46,792 | 154,243 | −5.07% | plan? |
| Aug 8, 2018 SForm 4 → | Aug 9, 4:05 pm EDT | Iain StuartSVP R&D | 2,715 | $5.68 | $15,421 | 34,285 | −7.34% | plan? |
| Jul 13, 2018 MForm 4 → | Jul 13, 4:08 pm EDT | Stanley HirschDirector | 1,616 | — | — | 12,974 | — | plan? |
| Jul 2, 2018 SForm 4 → | Jul 3, 4:09 pm EDT | David DomzalskiCEO, Director | 602 | $5.10 | $3,070 | 162,481 | −0.37% | plan? |
| Jul 2, 2018 SForm 4 → | Jul 3, 4:07 pm EDT | Alvin D HowardVP Regulatory | 234 | $5.10 | $1,193 | 42,023 | −0.55% | plan? |
| Jul 2, 2018 SForm 4 → | Jul 3, 4:05 pm EDT | Russell P. ElliottVP Drug Development | 142 | $5.10 | $724 | 12,584 | −1.12% | plan? |
| Jun 1, 2018 SForm 4 → | Jun 4, 2:20 pm EDT | David DomzalskiCEO, Director | 67 | $5.26 | $352 | 163,083 | −0.04% | plan? |
| May 13, 2018 SForm 4 → | May 31, 4:51 pm EDT | Stanley HirschDirector | 6,164 | $5.09 | $31,369 | 6,508 | −48.6% | plan? late |
| May 13, 2018 XForm 4 → | May 31, 4:51 pm EDT | Stanley HirschDirector | 6,224 | $5.04 | $31,369 | 12,672 | — | plan? late |
| May 8, 2018 AForm 4 → | May 10, 5:40 pm EDT | Anna KazanchyanDirector | 14,829 | — | — | 27,760 | — | plan? |
| May 8, 2018 AForm 4 → | May 10, 5:30 pm EDT | David DomzalskiCEO, Director | 23,396 | — | — | 163,150 | — | plan? |
| Apr 2, 2018 SForm 4 → | Apr 4, 12:32 pm EDT | Alvin D HowardVP Regulatory | 234 | $5.08 | $1,189 | 42,257 | −0.55% | plan? |
| Apr 2, 2018 SForm 4 → | Apr 4, 12:30 pm EDT | Russell P. ElliottVP Drug Development | 142 | $5.08 | $721 | 12,726 | −1.10% | plan? |
| Apr 2, 2018 SForm 4 → | Apr 4, 12:28 pm EDT | David DomzalskiCEO, Director | 602 | $5.08 | $3,058 | 139,754 | −0.43% | plan? |
| Mar 2, 2018 SForm 4 → | Mar 6, 11:50 am EST | Russell P. ElliottVP Drug Development | 817 | $6.14 | $5,016 | 12,868 | −5.97% | plan? |
| Mar 1, 2018 SForm 4 → | Mar 5, 11:37 am EST | David DomzalskiCEO, Director | 66 | $5.95 | $393 | 140,356 | −0.05% | plan? |
| Feb 27, 2018 AForm 4 → | Feb 28, 4:17 pm EST | David SchuzVP Intellectual Property | 5,000 | — | — | 24,980 | — | plan? |
| Feb 27, 2018 AForm 4 → | Feb 28, 4:15 pm EST | Mitchell ShirvanVP Innovation & Discovery | 5,000 | — | — | 24,980 | — | plan? |
| Feb 27, 2018 AForm 4 → | Feb 28, 4:13 pm EST | Ilan HadarCFO & Country Manager | 11,698 | — | — | 92,379 | — | plan? |
| Feb 27, 2018 AForm 4 → | Feb 28, 4:12 pm EST | Iain StuartSVP R&D | 10,000 | — | — | 37,000 | — | plan? |
| Feb 27, 2018 AForm 4 → | Feb 28, 4:11 pm EST | Alvin D HowardVP Regulatory | 7,500 | — | — | 42,491 | — | plan? |
| Feb 27, 2018 AForm 4 → | Feb 28, 4:09 pm EST | Yohan HazotVP Pharmaceutical Development | 5,000 | — | — | 32,300 | — | plan? |
| Feb 27, 2018 AForm 4 → | Feb 28, 4:07 pm EST | Mutya HarschGeneral Counsel and SVP | 25,000 | — | — | 25,000 | — | plan? |
| Feb 27, 2018 AForm 4 → | Feb 28, 4:05 pm EST | Russell P. ElliottVP Drug Development | 8,750 | — | — | 13,685 | — | plan? |
| Jan 2, 2018 SForm 4 → | Jan 18, 5:10 pm EST | Meir EiniOther | 40,000 | $6.29 | $251,761 | 2,717,781 | −1.45% | plan? late |
| Jan 1, 2018 MForm 4 → | Jan 24, 8:30 pm EST | David SchuzVP IP | 3,307 | — | — | 19,980 | — | plan? late |
| Jan 1, 2018 MForm 4 → | Jan 24, 8:29 pm EST | Mitchell ShirvanVP Innovation & Discovery | 3,307 | — | — | 19,980 | — | plan? late |
| Jan 1, 2018 MForm 4 → | Jan 24, 8:27 pm EST | Ilan HadarCFO & Country Manager | 5,594 | — | — | 80,681 | — | plan? late |
| Jan 1, 2018 FMForm 4 → | Jan 24, 8:26 pm EST | Russell P. ElliottVP Drug Development | 1,927 | $5.98 | $3,319 | 4,935 | — | plan? late |
| Jan 1, 2018 FMForm 4 → | Jan 24, 8:24 pm EST | David DomzalskiCEO, Director | 8,345 | $5.98 | $14,334 | 140,422 | — | plan? late |
| Jan 1, 2018 FMForm 4 → | Jan 24, 8:22 pm EST | Alvin D HowardVP Regulatory | 3,212 | $5.98 | $5,526 | 34,991 | — | plan? late |
| Jan 1, 2018 MForm 4 → | Jan 24, 8:21 pm EST | Yohan HazotVP Pharmaceutical Development | 5,137 | — | — | 27,300 | — | plan? late |
| Jan 1, 2018 MForm 4 → | Jan 18, 5:10 pm EST | Meir EiniOther | 6,157 | — | — | 17,396 | — | plan? late |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 1, 2019 AForm 4 → | Jan 3, 4:09 pm EST | Ilan HadarCFO & Country Manager | 94,996 | $3.81 | $361,935 | 94,996 | — | |
| Jan 1, 2019 AForm 4 → | Jan 3, 4:08 pm EST | Iain StuartChief Scientific Officer | 75,997 | $3.77 | $286,509 | 75,997 | — | |
| Jan 1, 2019 AForm 4 → | Jan 3, 4:06 pm EST | Mutya HarschCLO and General Counsel | 70,297 | $3.77 | $265,020 | 70,297 | — | |
| Jan 1, 2019 AForm 4 → | Jan 3, 4:04 pm EST | David DomzalskiCEO, Director | 170,993 | $3.77 | $644,644 | 170,993 | — | |
| Dec 3, 2018 AForm 4 → | Dec 4, 4:05 pm EST | Matthew T. WileyChief Commercial Officer | 100,000 | — | — | 100,000 | — | |
| Jul 13, 2018 MForm 4 → | Jul 13, 4:08 pm EDT | Stanley HirschDirector | 1,616 | — | — | 0 | — | |
| May 13, 2018 XForm 4 → | May 31, 4:51 pm EDT | Stanley HirschDirector | 6,224 | — | — | 0 | — | late |
| May 8, 2018 AForm 4 → | May 10, 5:38 pm EDT | Rex BrightDirector | 24,947 | — | — | 24,947 | — | |
| May 8, 2018 AForm 4 → | May 10, 5:36 pm EDT | Stanley HirschDirector | 49,766 | — | — | 49,766 | — | |
| May 8, 2018 AForm 4 → | May 10, 5:34 pm EDT | Darrell S RigelDirector | 24,947 | — | — | 24,947 | — | |
| May 8, 2018 AForm 4 → | May 10, 5:30 pm EDT | David DomzalskiCEO, Director | 70,187 | — | — | 70,187 | — | |
| May 8, 2018 AForm 4 → | May 10, 5:27 pm EDT | Stanley SternDirector | 24,947 | — | — | 24,947 | — | |
| May 8, 2018 AForm 4 → | May 10, 5:24 pm EDT | Aharon SchwartzDirector | 24,883 | — | — | 24,883 | — | |
| May 8, 2018 AForm 4 → | May 10, 5:21 pm EDT | Dalia MegiddoDirector | 24,883 | — | — | 24,883 | — | |
| Feb 27, 2018 AForm 4 → | Feb 28, 4:17 pm EST | David SchuzVP Intellectual Property | 15,000 | $6.40 | $96,000 | 15,000 | — | |
| Feb 27, 2018 AForm 4 → | Feb 28, 4:15 pm EST | Mitchell ShirvanVP Innovation & Discovery | 15,000 | $6.40 | $96,000 | 15,000 | — | |
| Feb 27, 2018 AForm 4 → | Feb 28, 4:13 pm EST | Ilan HadarCFO & Country Manager | 35,093 | $6.40 | $224,595 | 35,093 | — | |
| Feb 27, 2018 AForm 4 → | Feb 28, 4:12 pm EST | Iain StuartSVP R&D | 30,000 | $6.35 | $190,500 | 30,000 | — | |
| Feb 27, 2018 AForm 4 → | Feb 28, 4:11 pm EST | Alvin D HowardVP Regulatory | 22,500 | $6.35 | $142,875 | 22,500 | — | |
| Feb 27, 2018 AForm 4 → | Feb 28, 4:09 pm EST | Yohan HazotVP Pharmaceutical Development | 15,000 | $6.40 | $96,000 | 15,000 | — | |
| Feb 27, 2018 AForm 4 → | Feb 28, 4:07 pm EST | Mutya HarschGeneral Counsel and SVP | 50,000 | $6.35 | $317,500 | 50,000 | — | |
| Feb 27, 2018 AForm 4 → | Feb 28, 4:05 pm EST | Russell P. ElliottVP Drug Development | 26,250 | $6.35 | $166,688 | 26,250 | — | |
| Jan 1, 2018 MForm 4 → | Jan 24, 8:30 pm EST | David SchuzVP IP | 3,307 | — | — | 0 | — | late |
| Jan 1, 2018 MForm 4 → | Jan 24, 8:29 pm EST | Mitchell ShirvanVP Innovation & Discovery | 3,307 | — | — | 0 | — | late |
| Jan 1, 2018 MForm 4 → | Jan 24, 8:27 pm EST | Ilan HadarCFO & Country Manager | 5,594 | — | — | 0 | — | late |
| Jan 1, 2018 MForm 4 → | Jan 24, 8:26 pm EST | Russell P. ElliottVP Drug Development | 1,372 | — | — | 0 | — | late |
| Jan 1, 2018 MForm 4 → | Jan 24, 8:24 pm EST | David DomzalskiCEO, Director | 5,948 | — | — | 0 | — | late |
| Jan 1, 2018 MForm 4 → | Jan 24, 8:22 pm EST | Alvin D HowardVP Regulatory | 2,288 | — | — | 0 | — | late |
| Jan 1, 2018 MForm 4 → | Jan 24, 8:21 pm EST | Yohan HazotVP Pharmaceutical Development | 5,137 | — | — | 0 | — | late |
| Jan 1, 2018 MForm 4 → | Jan 18, 5:10 pm EST | Meir EiniOther | 6,157 | — | — | 4,500 | — | late |